Non-Hodgkin’s Lymphoma

FDA Approves Aliqopa for Treatment of Adults with Relapsed Follicular Lymphoma (10-18-2017)

The U.S. Food and Drug Administration today granted accelerated approval to Aliqopa (copanlisib) for the treatment of adults with relapsed follicular lymphoma who have received at least two prior treatments known as systemic therapies. “For patients... Continue Reading

Duvelisib; Promising New Treatment Option for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (09-11-2017)

Results of the Phase 3 DUO study evaluating duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) have been reported and appear very promising.  Although the treatment of CLL/SLL has advanced... Continue Reading

Routine CT Scans May Not Be Necessary for Many Lymphoma Survivors (06-25-2013)

After treatment for diffuse large B cell lymphoma (DLBCL), only a small minority of patients have a relapse detected through routine surveillance CT scans alone, suggesting that routine scans have limited value for these patients. These results were presented... Continue Reading

Two Different Approaches to Rituxan Both Effective For Follicular Lymphoma (02-10-2012)

Among patients with low-tumor-burden follicular lymphoma who have received initial treatment with Rituxan® (rituximab), waiting until disease progression to take additional Rituxan is as effective as ongoing, maintenance Rituxan. These results were presented... Continue Reading

Additional Rare Cancer Cases Reported Among Users of TNF Blockers (04-19-2011)

The US Food and Drug Administration (FDA) has received additional reports of a rare type of cancer—hepatosplenic T-cell lymphoma—primarily among adolescents and young adults who are being treated for Crohn’s disease or ulcerative colitis with medications... Continue Reading

Maintenance Rituxan® Prolongs Survival in Advanced Indolent Lymphoma (03-31-2009)

Maintenance Rituxan® (rituximab) given after standard chemotherapy significantly prolongs progression-free survival (PFS) in patients with advanced-stage indolent non-Hodgkin’s lymphoma, according to the results of a study published in the Journal... Continue Reading

Understanding Targeted Therapy for Non-Hodgkin’s Lymphoma (02-6-2009)

Targeted therapies are anticancer drugs that are designed to treat cancer cells while minimizing damage to normal, healthy cells. These drugs, which may be used in the treatment of non-Hodgkin’s lymphoma, interfere with specific pathways involved in... Continue Reading

Lymphoma Patients: Understanding Peripheral Neuropathy (02-6-2009)

If you’ve received chemotherapy as part of your lymphoma treatment, one of the side effects you may experience is numbness and tingling in you extremities, also known as peripheral neuropathy. The following guidelines explain how to recognize and manage... Continue Reading

It’s Not Just a Little Fever: Preventing Infection during Therapy for Lymphoma (02-6-2009)

Many cancer patients are at an increased risk of infection because of their low levels of infection-fighting white blood cells, a condition called neutropenia. The most common reason that cancer patients experience neutropenia is as a side effect of chemotherapy.... Continue Reading

Successful Treatment for Lymphoma Means Staying on Schedule (02-6-2009)

In order to receive the best possible benefit from your lymphoma therapy, it is important to follow your treatment as your doctor has prescribed. Even if you’re not able to visit your regular treatment facility, chances are good that you can still... Continue Reading

« Previous PageNext Page »